Study of First-Line Aumolertinib Plus Bevacizumab and Pemetrexed Treated NSCLC with EGFR Mutation and Brain Metastasis

被引：0
|
作者：
Fu, S. [1 ]
Liu, J. [1 ]
Fu, P. [2 ]
Li, H. [3 ]
Yang, X. [3 ]
Xie, C. [1 ]
Zhang, J. [1 ]
机构：
[1] Shandong Univ, Shandong Canc Hosp & Inst, Jinan, Peoples R China
[2] Jinan Zhangqiu Dist Peoples Hosp, Jinan, Peoples R China
[3] Qingdao Univ, Affiliated Hosp, Qingdao, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2022年 / 17卷 / 09期
关键词：
EGFR mutant NSCLC; Brain Metastasis; Aumolertinib combination therapy;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP08.02-03
引用
收藏
页码：S414 / S415
页数：2
相关论文
共 50 条
  • [41] Outcomes of First-Line TKI Treated Advanced NSCLC with Distinct Types of EGFR Mutations: Brain Metastasis and de Novo T790M
    Zeng, Y.
    Ni, J.
    Guo, T.
    Yang, X.
    Chu, L.
    Chu, X.
    Zhu, Z.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1121 - S1121
  • [42] Pemetrexed mit Cisplatin in der Erstlinientherapie des NSCLCPemetrexed plus cisplatin as first-line therapy for NSCLC
    N.J. Dickgreber
    Der Pneumologe, 2009, 6 (3): : 176 - 178
  • [43] Optimal first-line therapy for NSCLC with EGFR mutations
    Joel W. Neal
    Lecia V. Sequist
    Nature Reviews Clinical Oncology, 2010, 7 : 71 - 72
  • [44] NSCLC with uncommon EGFR mutations treated with atezolizumab plus bevacizumab and chemotherapy
    Trummer, Arne
    Bethge, Andre
    Dickgreber, Nicolas
    Dittrich, Ina
    Golpon, Heiko
    Hoffknecht, Petra
    Overbeck, Tobias R.
    Wesseler, Claas
    Reck, Martin
    LUNG CANCER, 2022, 174 : 141 - 145
  • [45] Antacid and de novo brain metastases in EGFR-mutant NSCLC patients treated with first-line, first-generation EGFR-TKIs
    Chen, Y-M.
    Lin, M-C.
    Lai, C-H.
    Fang, W-F.
    Chang, H-C.
    Wang, C-C.
    Tseng, C-C.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S132 - S132
  • [46] 65 plus: A randomized phase III trial of pemetrexed and bevacizumab versus pemetrexed, bevacizumab, and carboplatin as first-line treatment for elderly patients with advanced nonsquamous, non-small cell lung cancer (NSCLC).
    Schuette, Wolfgang
    Nagel, Sylke
    Schneider, Claus-Peter
    Engel-Riedel, Walburga
    Schumann, Christian
    Kohlhaeufl, Martin
    Serke, Monika
    Hoeffken, Gert
    Kortsik, Cornelius
    Reck, Martin
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [47] Liver Metastases Is the Negative Predictive Factor for First-Line EGFR TKIs Therapy in NSCLC Patients with EGFR Mutation
    Jiang, Tao
    Zhou, Caicun
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1246 - S1247
  • [48] Comparison of EGFR-TKI and chemotherapy in the first-line treatment of advanced EGFR mutation-positive NSCLC
    Fiala, O.
    Pesek, M.
    Finek, J.
    Benesova, L.
    Bortlicek, Z.
    Minarik, M.
    NEOPLASMA, 2013, 60 (04) : 425 - 431
  • [49] EGFR Inhibitors Plus Bevacizumab are Superior Than EGFR Inhibitors Alone as First-Line Setting in Advanced NSCLC With EGFR Mutations and BIM Deletion Polymorphisms (BIM-CLICaP)
    Cardona, Andres F.
    Ordonez-Reyes, Camila
    Ruiz-Patino, Alejandro
    Garcia-Robledo, Juan Esteban
    Barron, Lucia Zatarain
    Recondo, Gonzalo
    Rojas, Leonardo
    Corrales, Luis
    Martin, Claudio
    Barron, Feliciano
    Sotelo, Carolina
    Rodriguez, July
    Ricaurte, Luisa
    Rolfo, Christian
    Avila, Jenny
    Mayorga, Diana
    Archila, Pilar
    Otero, Jorge
    Mas, Luis
    Bermudez, Maritza
    Gamez, Tatiana
    Carranza, Hernan
    Vargas, Carlos
    Rosell, Rafael
    Arrieta, Oscar
    JCO PRECISION ONCOLOGY, 2021, 5 : 839 - 848
  • [50] EGFR Inhibitors plus Bevacizumab Demonstrated Superior Efficacy Compared with EGFR Inhibitors Alone as First-line Treatment in Advanced NSCLC Patients with EGFR Mutations and BIM Deletion Polymorphisms
    Cardona, A. F.
    Arrieta, O.
    Ruiz-Patino, A.
    Zatarain Barron, L.
    Corrales-Rodriguez, L.
    Martin, C.
    Barron, F.
    Sotelo, C.
    Rodriguez, J.
    Ricaurte, L.
    Avila, J.
    Mayorga, D.
    Archila, P.
    Otero, J.
    Freitas, H.
    Cordeiro De Lima, V. C.
    Mas, L.
    Carranza, H.
    Vargas, C.
    Rosell, R.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (11) : S1172 - S1173
12345